Karo Bio is a drug discovery and development company specializing in endocrinology and targeting nuclear receptors as target proteins for the development of novel pharmaceuticals. Karo Bio is listed on NASDAQ OMX Stockholm since 1998 (Reuters: KARO.ST).
 
The company has a project portfolio with innovative pharmaceutical compounds that primarily target dyslipidemia, CNS disorders, inflammation, and women’s health. In these areas, there are significant market opportunities and a clear need for pharmaceuticals with new mechanisms of action. Karo Bio has the capacity to bring selected compounds in therapeutic niche areas into late stage clinical development and, potentially, registration, while the intention is to out-license compounds aimed at treating broad patient populations at the latest when clinical proof of concept has been obtained in clinical phase II studies.
 
In addition to the proprietary projects, Karo Bio has three strategic collaborations with international pharmaceutical companies for development of innovative therapies for the treatment of common diseases.